Aerie Pharmaceuticals CEO Vicente Anido's 2018 pay falls 33% to $6.8M
Aerie Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 10, 2019
Aerie Pharmaceuticals reported fiscal year 2018 executive compensation information on April 10, 2019.
In 2018, five executives at Aerie Pharmaceuticals received on average a compensation package of $3.9M, a 21% decrease compared to previous year.
Average pay of disclosed executives at Aerie Pharmaceuticals
Vicente Anido, Jr., Chief Executive Officer, received $6.8M in total, which decreased by 33% compared to 2017. 63% of Anido's compensation, or $4.3M, was in option awards. Anido also received $410K in non-equity incentive plan, $750K in salary, as well as $1.4M in stock awards.
John W. LaRocca, General Counsel, received a compensation package of $4.2M. 64% of the compensation package, or $2.7M, was in option awards.
Thomas A. Mitro, Chief Operating Officer, earned $3.4M in 2018, a 26% decrease compared to previous year.
Richard J. Rubino, Chief Financial Officer, received $3M in 2018, which decreases by 7% compared to 2017.
Casey C. Kopczynski, Chief Scientific Officer, earned $2.3M in 2018, a 17% increase compared to previous year.
Related executives
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
Casey Kopczynski
Aerie Pharmaceuticals
Chief Innovation Officer, Head of Research and External Innovation
John LaRocca
Aerie Pharmaceuticals
General Counsel
You may also like
Source: SEC filing on April 10, 2019.